Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer
Citations
6 citations
References
10,532 citations
"Checkpoint Kinase 1 Pharmacological..." refers background in this paper
...This has been the case with the identification of HER2 amplification in breast cancer, which led to the design of antibodies or small tyrosine kinase inhibitors against this protein [3,4]....
[...]
6,773 citations
"Checkpoint Kinase 1 Pharmacological..." refers background in this paper
...In line with this, other investigational compounds have reached the clinical setting, including B-RAF or MEK inhibitors in BRAF (V600E)-mutant tumors such as melanoma or non-small cell lung cancer [5,6]....
[...]
4,287 citations
"Checkpoint Kinase 1 Pharmacological..." refers methods or result in this paper
...To explore whether the administration of rabusertib was synergistic with any of the chemotherapies mentioned, we used the Chou and Talalay method [20,21]....
[...]
...Results in line with these findings have been observed in other tumor types such as bladder, pancreatic, or colon cancer [20,22]....
[...]
1,927 citations
"Checkpoint Kinase 1 Pharmacological..." refers background in this paper
...We also included olaparib, a PARP inhibitor that has recently been approved for the treatment of breast cancers with germ line mutations of the BRCA gene [19]....
[...]
1,643 citations
"Checkpoint Kinase 1 Pharmacological..." refers background in this paper
...Targeted therapies can also be designed against proteins or pathways that can establish a synthetic lethality interaction when combined with other agents [7,8]....
[...]
...The inhibition of a single pathway causes cells to be more dependent on other routes to maintain cell survival; therefore, those survival routes are optimal targets for drug inhibition [8]....
[...]